Research study for adults with NASH Cirrhosis

UVA Tracking #
HSR210322
Principal Investigator
Stephen H Caldwell
Contact
Jennifer Greene
Contact Email
Contact Phone
434.982.0709
Official Trial Title
A Phase 2, Randomized, Double-Blind, Double-Dummy,
Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (
Study Description

The GI Hepatology Department seeks adults ages 18-80 with NASH cirrhosis for a research study. The purpose of the study is to determine if semaglutide (an approved drug for diabetes) used in combination with 2 unapproved drugs (cilofexor and firsocostat) causes liver fibrosis to improve.

Study involves taking experimental medicine/placebo, blood draws, liver biopsy, EKGs, Fibroscan, eye exam, abdominal ultrasound and physical exams. Study involves at least 14 visits over approximately 85 weeks. Most visits will last about an hour.

Study-related exams, tests and medication provided free of charge.

Compensation

$75/visit